Use of immunocorrectors in patients with chronic lymph leukemia
- Authors: Shustov V.Y.1, Afanasyeva N.A.1, Kuznetsov P.P.1, Myshkina A.K.1
-
Affiliations:
- Saratov Medical Institute
- Issue: Vol 67, No 2 (1986)
- Pages: 99-101
- Section: Articles
- URL: https://ogarev-online.ru/kazanmedj/article/view/65309
- DOI: https://doi.org/10.17816/kazmj65309
- ID: 65309
Cite item
Full Text
Abstract
Chronic lymphatic leukemia is second only to acute leukemia in the frequency of infectious complications. In most cases, severe infectious complications are the cause of death in these patients. Modern chemotherapy makes it possible to preserve the ability to work and the life expectancy of patients for a long time. However, the negative effect of cytostatic drugs on the already altered immune system leads to an even greater suppression of immunity and an increase in the number of infectious complications. The search for new ways to combat infections has shown the advisability of long-term outpatient treatment with antibacterial drugs.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
V. Ya. Shustov
Saratov Medical Institute
Author for correspondence.
Email: info@eco-vector.com
Russian Federation
N. A. Afanasyeva
Saratov Medical Institute
Email: info@eco-vector.com
Russian Federation
P. P. Kuznetsov
Saratov Medical Institute
Email: info@eco-vector.com
Russian Federation
A. K. Myshkina
Saratov Medical Institute
Email: info@eco-vector.com
Russian Federation
References
Supplementary files
